Nectin Therapeutics Announces Extended Series A Financing to Over $25M and Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors

─First-in-Human Phase 1 Clinical Trial in Advanced Solid Tumors is Being Conducted by MD Anderson with an Investment from Cancer Focus Fund ─ ─Extension Brings in New Investor Israel Biotech Fund (IBF), with Additional Participation from Existing Investors ─ JERUSALEM and FORT LEE, NJ,…

Click here to view original post